
    
      All eligible patients will receive:

        -  Bevacizumab 10mg/kg, IV infusion, every 2 weeks

        -  RAD001 10 mg by mouth daily

      All patients will be evaluated for response after completing two courses (8 weeks) of
      treatment. Patients with objective tumor response or stable disease will continue treatment
      with bevacizumab adn RAD001 on the same schedule. Treatment will continue until disease
      progression occurs.
    
  